Coverage with evidence development: Difference between revisions

From Glossary for Health Technology Lifecycle by EuroScan
(Created page with "Early funding of a health technology conditional on gathering additional evidence to address the sources of uncertainty. '''Note 1:''' The uncertainty usually relates to a specific aspect of the effectiveness or cost-effectiveness. '''Note 2:''' Synonyms include access with evidence development, and managed access. '''Note 3:''' Related terms include managed entry scheme/agreement, risk share agreement, interim funding, evidence development, conditional reimbursement,...")
 
No edit summary
 
Line 7: Line 7:
'''Note 3:''' Related terms include managed entry scheme/agreement, risk share agreement, interim funding, evidence development, conditional reimbursement, and [[conditional coverage]].
'''Note 3:''' Related terms include managed entry scheme/agreement, risk share agreement, interim funding, evidence development, conditional reimbursement, and [[conditional coverage]].


[http://htaglossary.net/coverage-with-evidence-development]
== References ==
http://htaglossary.net/coverage-with-evidence-development

Latest revision as of 12:56, 21 November 2023

Early funding of a health technology conditional on gathering additional evidence to address the sources of uncertainty.

Note 1: The uncertainty usually relates to a specific aspect of the effectiveness or cost-effectiveness.

Note 2: Synonyms include access with evidence development, and managed access.

Note 3: Related terms include managed entry scheme/agreement, risk share agreement, interim funding, evidence development, conditional reimbursement, and conditional coverage.

References

http://htaglossary.net/coverage-with-evidence-development